Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Repetitive transcranial magnetic stimulation for specific patient populations: clinical and cost-effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions Overall, for patients with depression, there appears to be a significant improvement with rTMS treatment of duration >2 weeks or >10 sessions when compared to sham. For patients with auditory hallucination or obsessive compulsive disorder there appears to be no significant improvement with rTMS treatment of duration >2 weeks or >10 sessions when compared to sham. No relevant evidence was identified for rTMS treatment for substance use disorders. Indexing Status Subject indexing assigned by CRD MeSH Cost-Benefit Analysis; Transcranial Magnetic Stimulations Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000231 Date abstract record published 24/01/2014 |